These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 9315542)

  • 21. Catheter ablation of hemodynamically unstable ventricular tachycardia with mechanical circulatory support.
    Lü F; Eckman PM; Liao KK; Apostolidou I; John R; Chen T; Das GS; Francis GS; Lei H; Trohman RG; Benditt DG
    Int J Cardiol; 2013 Oct; 168(4):3859-65. PubMed ID: 23863501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ventricular Tachycardia and ICD Therapy Burden With Catheter Ablation Versus Escalated Antiarrhythmic Drug Therapy.
    Samuel M; Healey JS; Nault I; Sterns LD; Essebag V; Gray C; Hruczkowski T; Gardner M; Parkash R; Sapp JL
    JACC Clin Electrophysiol; 2023 Jun; 9(6):808-821. PubMed ID: 37380314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%.
    Maury P; Baratto F; Zeppenfeld K; Klein G; Delacretaz E; Sacher F; Pruvot E; Brigadeau F; Rollin A; Andronache M; Maccabelli G; Gawrysiak M; Brenner R; Forclaz A; Schlaepfer J; Lacroix D; Duparc A; Mondoly P; Bouisset F; Delay M; Hocini M; Derval N; Sadoul N; Magnin-Poull I; Klug D; Haïssaguerre M; Jaïs P; Della Bella P; De Chillou C
    Eur Heart J; 2014 Jun; 35(22):1479-85. PubMed ID: 24536081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].
    Tanner H; Hindricks G; Kottkamp H
    Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era.
    Mittal S; Iwai S; Stein KM; Markowitz SM; Slotwiner DJ; Lerman BB
    J Am Coll Cardiol; 1999 Oct; 34(4):1082-9. PubMed ID: 10520794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings.
    Della Bella P; De Ponti R; Uriarte JA; Tondo C; Klersy C; Carbucicchio C; Storti C; Riva S; Longobardi M
    Eur Heart J; 2002 Mar; 23(5):414-24. PubMed ID: 11846499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
    Arenal Á; Ávila P; Jiménez-Candil J; Tercedor L; Calvo D; Arribas F; Fernández-Portales J; Merino JL; Hernández-Madrid A; Fernández-Avilés FJ; Berruezo A
    J Am Coll Cardiol; 2022 Apr; 79(15):1441-1453. PubMed ID: 35422240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up after hemodynamically not tolerated ventricular tachycardia in patients with midrange reduced to normal ejection fraction: A retrospective single-centre case series.
    Groeneveld SA; Blom LJ; van der Heijden JF; Loh P; Hassink RJ
    Eur J Clin Invest; 2021 Jan; 51(1):e13359. PubMed ID: 32705678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Endocardial mapping and high frequency catheter ablation of ventricular tachycardia after myocardial infarction].
    Willems S; Weiss C; Meinertz T
    Z Kardiol; 2000; 89 Suppl 3():161-70. PubMed ID: 10810799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
    Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of cardiac sarcoidosis after radiofrequency ablation and placement of AICD- A propensity matched analysis.
    Bandyopadhyay D; Sahoo D; Zein J; Brunken RC; Tchou PJ; Culver DA
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jun; 32(1):70-9. PubMed ID: 26237358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial.
    Tung R; Xue Y; Chen M; Jiang C; Shatz DY; Besser SA; Hu H; Chung FP; Nakahara S; Kim YH; Satomi K; Shen L; Liang E; Liao H; Gu K; Jiang R; Jiang J; Hori Y; Choi JI; Ueda A; Komatsu Y; Kazawa S; Soejima K; Chen SA; Nogami A; Yao Y;
    Circulation; 2022 Jun; 145(25):1839-1849. PubMed ID: 35507499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator.
    Sauer WH; Zado E; Gerstenfeld EP; Marchlinski FE; Callans DJ
    Heart Rhythm; 2010 Jan; 7(1):9-14. PubMed ID: 19939743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catheter Ablation of Ventricular Tachycardia as the First-Line Therapy in Patients With Coronary Artery Disease and Preserved Left Ventricular Systolic Function: Long-Term Results.
    Clemens M; Peichl P; Wichterle D; Pavlů L; Čihák R; Aldhoon B; Kautzner J
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1105-10. PubMed ID: 26179108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease.
    Morady F; Harvey M; Kalbfleisch SJ; el-Atassi R; Calkins H; Langberg JJ
    Circulation; 1993 Feb; 87(2):363-72. PubMed ID: 8425285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction.
    Stevenson WG; Khan H; Sager P; Saxon LA; Middlekauff HR; Natterson PD; Wiener I
    Circulation; 1993 Oct; 88(4 Pt 1):1647-70. PubMed ID: 8403311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-density substrate-guided ventricular tachycardia ablation: role of activation mapping in an attempt to improve procedural effectiveness.
    Carbucicchio C; Ahmad Raja N; Di Biase L; Volpe V; Dello Russo A; Trivedi C; Bartoletti S; Zucchetti M; Casella M; Russo E; Santangeli P; Moltrasio M; Tundo F; Fassini G; Natale A; Tondo C
    Heart Rhythm; 2013 Dec; 10(12):1850-8. PubMed ID: 24055940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ablation of ventricular tachycardia in the very elderly patient with cardiomyopathy: how old is too old?
    Barra S; Begley D; Heck P; Turner I; Agarwal S
    Can J Cardiol; 2015 Jun; 31(6):717-22. PubMed ID: 25869352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation.
    Bai R; Di Biase L; Shivkumar K; Mohanty P; Tung R; Santangeli P; Saenz LC; Vacca M; Verma A; Khaykin Y; Mohanty S; Burkhardt JD; Hongo R; Beheiry S; Dello Russo A; Casella M; Pelargonio G; Santarelli P; Sanchez J; Tondo C; Natale A
    Circ Arrhythm Electrophysiol; 2011 Aug; 4(4):478-85. PubMed ID: 21665983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials.
    Atti V; Vuddanda V; Turagam MK; Vemula P; Shah Z; Nagam H; Yandrapalli S; Jazayeri MA; Koerber S; Gonzalez JV; Natale A; Di Biase L; Lakkireddy DR
    J Interv Card Electrophysiol; 2018 Nov; 53(2):207-215. PubMed ID: 29680972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.